Complete QLGN Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
QLGN DCF Analysis
QLGN (Qualigen Therapeutics, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2021 (Historical) | 2022 (Historical) | 2023 (Historical) | 2024 (Projected) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $5.0M | $5.2M | $5.3M | $5.4M | $5.5M | $5.6M | $5.7M |
| Revenue Growth % | - | -11.9% | 4.4% | 2.2% | 2.0% | 1.8% | 1.6% | 1.5% |
| EBIT | $-22.7M | $-17.9M | $-11.3M | $266.0K | $271.4K | $276.2K | $280.7K | $284.8K |
| EBIT Margin % | -400.9% | -360.0% | -217.2% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-17.0M | $-13.5M | $-8.5M | $199.5K | $203.5K | $207.2K | $210.5K | $213.6K |
| NOPAT Margin % | -300.6% | -270.0% | -162.9% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $141.4K | $319.1K | $0 | $183.9K | $178.2K | $172.4K | $166.4K | $160.4K |
| Capex / Revenue % | 2.5% | 6.4% | 0.0% | 3.5% | 3.3% | 3.1% | 3.0% | 2.8% |
| Depreciation | $338.3K | $375.6K | $4.5K | $241.3K | $246.1K | $250.6K | $254.6K | $258.4K |
| D&A / Revenue % | 6.0% | 7.5% | 0.1% | 4.5% | 4.5% | 4.5% | 4.5% | 4.5% |
| Change in NWC | $-1.6M | $-13.9M | $-5.2M | $0 | $0 | $0 | $0 | $0 |
| NWC Change / Revenue % | -28.9% | -279.9% | -99.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Unlevered FCF | $-15.2M | $548.2K | $-3.3M | $256.9K | $271.4K | $285.4K | $298.8K | $311.6K |
| UFCF % Chg. | - | 103.6% | -700.4% | 107.8% | 5.7% | 5.1% | 4.7% | 4.3% |
| FCF / Revenue % | -268.3% | 11.0% | -63.2% | 4.8% | 5.0% | 5.2% | 5.3% | 5.5% |
| Discount Factor | - | - | - | 0.956 | 0.914 | 0.874 | 0.835 | 0.798 |
| Present Value of FCF | - | - | - | $245.6K | $248.0K | $249.3K | $249.5K | $248.7K |
| Sum of PV of UFCF | - | - | - | $245.6K | $493.6K | $743.0K | $992.5K | $1.2M |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.8% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.1% |
| Risk Free Rate | 4.26% |
| Market Risk Premium | 4.3% |
| Beta | 0.03 |
| Cost of Equity | 4.4% |
| Total Debt | $1.3M |
| Market Cap | $2.6M |
| Total Capital | $3.9M |
| Debt Weighting | 33.1% |
| Equity Weighting | 66.9% |
| WACC | 4.6% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $311.6K |
| Terminal Value | $15.1M |
| PV of Terminal Value | $12.1M |
| Cumulative PV of UFCF | $1.2M |
| Net Debt | $897.4K |
| Equity Value | $12.4M |
| Shares Outstanding | 5.1M |
| Implied Share Price | $2 |
| Current Share Price | $4 |
| Implied Upside/(Downside) | -31.2% |
Valuation Summary
$2.45
Implied Price
$3.56
Current Price
-31.2%
Upside/Downside
4.6%
WACC
QLGN Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 6 peer companies in Healthcare
P/E Ratio
$0.00
-100.0%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$3.65
+2.5%
Peer Median: 0.6x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for QLGN's business model and current situation.
Multiple Comparison
| Multiple | QLGN Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.2x | 0.0x | 0.0x | -Infinity% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 0.6x | 0.6x | 0.6x | -2.5% | Fair Value |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.00B | 0.0x | 0.0x | 35.5x | |
| $0.00B | 0.0x | 0.0x | 30.5x | |
| $0.00B | 0.0x | 0.0x | 0.0x | |
| $0.00B | 0.0x | 0.0x | 0.6x | |
| $0.00B | 0.0x | 0.0x | 51.1x | |
| $0.00B | 0.0x | 0.0x | 0.0x |